Comments
Syngene International on Wednesday informed the bourses that it has entered into a pact with US-based Zumutor Biologics for biotherapeutic antibody discovery services.
As part of the non-exclusive partnering agreement, Syngene will have access to Zumutor’s proprietary naive human phage/yeast display library.
Under the agreement, Syngene will screen target antigens against Zumutor’s proprietary human antibody libraries to identify and characterise novel antibody clones, which will be further developed by Syngene towards novel biotherapeutics programmes for its partners.
This partnership will expand Syngene’s portfolio of therapeutic antibody discovery platforms. Shares of Syngene edged down 0.53 per cent at ₹605.5 on the NSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.